Targeting the pro-inflammatory factor CCL2 (MCP-1) with Bindarit for influenza A (H7N9) treatment.

about

Human CD36 overexpression in renal tubules accelerates the progression of renal diseases in a mouse model of folic acid-induced acute kidney injury.

P2860

Q55249146-CCAEF389-316A-46E4-B3AB-FAF5C54444E7

P2860

Targeting the pro-inflammatory factor CCL2 (MCP-1) with Bindarit for influenza A (H7N9) treatment.

Item

http://www.wikidata.org/entity/Q37739368

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 31 March 2017

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Targeting the pro-inflammatory ...... influenza A (H7N9) treatment.

@en

Targeting the pro-inflammatory factor CCL2

@nl

type

Item

label

Targeting the pro-inflammatory ...... influenza A (H7N9) treatment.

@en

Targeting the pro-inflammatory factor CCL2

@nl

prefLabel

Targeting the pro-inflammatory ...... influenza A (H7N9) treatment.

@en

Targeting the pro-inflammatory factor CCL2

@nl

P1476

Targeting the pro-inflammatory ...... influenza A (H7N9) treatment.

@en

P2093

Olivia Perwitasari

http://www.w3.org/2001/XMLSchema#string

Ralph A Tripp

http://www.w3.org/2001/XMLSchema#string

Scott Johnson

http://www.w3.org/2001/XMLSchema#string

Stefan Wolf

http://www.w3.org/2001/XMLSchema#string

P2860

Chemokine CCL2 and its receptor CCR2 are increased in the hippocampus following pilocarpine-induced status epilepticus

Amantadine and rimantadine for influenza A in adults

Bindarit, an inhibitor of monocyte chemotactic protein synthesis, protects against bone loss induced by chikungunya virus infection

CCR2 deficiency promotes exacerbated chronic erosive neutrophil-dominated chikungunya virus arthritis

Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method

Mechanisms of mononuclear phagocyte recruitment in Alzheimer's disease

The potential impact of neuraminidase inhibitor resistant influenza

Human infection with a novel avian-origin influenza A (H7N9) virus

Verdinexor, a novel selective inhibitor of nuclear export, reduces influenza a virus replication in vitro and in vivo.

Changes in and shortcomings of control strategies, drug stockpiles, and vaccine development during outbreaks of avian influenza A H5N1, H1N1, and H7N9 among humans.

P2888

cti.2017.8

P304

e135

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/CTI.2017.8

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Suresh Mahalingam

P577

2017-03-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1084127958

http://www.w3.org/2001/XMLSchema#string

P698

28435679

http://www.w3.org/2001/XMLSchema#string

P932

5382437

http://www.w3.org/2001/XMLSchema#string

Targeting the pro-inflammatory factor CCL2 (MCP-1) with Bindarit for influenza A (H7N9) treatment.

about

P2860

P2860

Targeting the pro-inflammatory factor CCL2 (MCP-1) with Bindarit for influenza A (H7N9) treatment.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P6179

P698

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P50

P577

P6179

P698

P932